As osteoclast-like GCs show largely similar expression profiles to osteoclasts, the specific anti RANK-L-antibody Denosumab may be beneficial in pathologies beyond GC tumour of the bone, such as aneurysmal bone cyst and chondroblastoma, for which off-label uses have been reported [14]. The gene discussed is TNFSF11; the disease is neoplasm.